ACET - Adicet Bio, Inc.
IEX Last Trade
0.9395
0.004 0.458%
Share volume: 6,347
Last Updated: Thu 26 Dec 2024 08:29:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.94
0.00
0.46%
Fundamental analysis
25%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
25%
Performance
5 Days
2.52%
1 Month
-4.59%
3 Months
-34.56%
6 Months
-31.63%
1 Year
-44.81%
2 Year
-88.13%
Key data
Stock price
$0.94
DAY RANGE
$0.88 - $0.94
52 WEEK RANGE
$0.91 - $3.77
52 WEEK CHANGE
-$47.34
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Chen Schor
Region: US
Website: adicetbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: adicetbio.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
Recent news